| Name | dinutuximab |
|---|
| Description | Dinutuximab (Unituxin; APN-311) is a chimeric, human-murine, anti-GD2 monoclonal antibody. Dinutuximab potently enlongs event-free survival and overall survival, in high-risk neuroblastoma treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA])[1]. |
|---|---|
| Related Catalog | |
| Target |
GD2[1] |
| References |
| No Any Chemical & Physical Properties |